NCT02140138View on ClinicalTrials.gov

An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Prostate Carcinoma
Interventions
BIOLOGICAL

CV9104

DEVICE

needle free injection device (Tropis®)

Trial Locations (3)

69120

Nationales Zentrum für Tumorerkrankungen, Medizinische Onkologie, Heidelberg

72076

Klinik für Urologie, Universitätsklinikum Tübingen, Tübingen

81675

Klinikum rechts der Isar, Urologische Klinik und Poliklinik der Technischen Universität München, München

Sponsors

Lead Sponsor

CureVac
All Listed Sponsors
lead

CureVac

INDUSTRY

NCT02140138 - An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter